Gram-Negative Antibiotic Discovery Innovator (Gr-ADI)
The Gr-ADI initiative seeks proposals for early drug discovery of broad-spectrum antibiotics against Enterobacteriaceae, using Klebsiella spp., to combat antimicrobial resistance.
This grant is no longer accepting proposals
Bill and Melinda Gates Foundation has archived this opportunity.
Funder: Bill & Melinda Gates Foundation
Due Dates: June 30, 2025 (Notification of full proposal invitation)
Funding Amounts: Up to $5,000,000 USD per project for up to 3 years; exploratory projects with lower budgets and shorter durations are encouraged.
Summary: Supports early-stage discovery of broad-spectrum, direct-acting small molecule antibiotics against Enterobacteriaceae (using Klebsiella spp.) to address antimicrobial resistance.
Key Information: Applicants must agree to consortium-wide data sharing and be able to accept the terms of at least one of the three funders (Gates Foundation, Wellcome, NNF).
Description
The Gram-Negative Antibiotic Discovery Innovator (Gr-ADI) initiative is a collaborative funding opportunity from the Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation. It aims to catalyze early-stage drug discovery for Gram-negative pathogens, specifically targeting the development of new, broad-spectrum, direct-acting small molecule antibiotics against Enterobacteriaceae, with a focus on Klebsiella spp. The program is structured as a consortium, fostering collaboration and data sharing among grantees to accelerate progress and maximize impact in the fight against antimicrobial resistance (AMR).
Projects funded under this initiative will contribute to a portfolio of innovative approaches, including the development of new biological, chemical, and AI tools for antibiotic discovery, and the generation of chemical starting points for further drug development. All funded projects will operate under a consortium-wide data sharing agreement to promote synergy and collective advancement.
